STUDIES

id.DRIVE carries out different studies under a common data collection. Three studies are currently running: a respiratory viruses surveillance study, a COVID-19 Vaccine Effectiveness study (CVE), and a respiratory syncytial virus (RSV VE) Vaccine Effectiveness study.

Patient recruitment started in September 2021 for the COVID-19 CVE study. The common data collection was launched on 26 July 2024 by including the surveillance study data, followed by RSV VE data collection in fall 2024, and the multi-specimen pilot study in early 2026. As of 11 of February 2026, a total of 33,041 patients have been recruited across 42 hospitals from 21 Study Contributors in 7 European countries.

Surveillance of respiratory viruses

  • This yearly study started on 26 July 2024 and acts as an umbrella for the common data collection that feeds the VE studies.
  • Multi-country hospital-based study monitoring viral respiratory infections in adults hospitalised for severe acute respiratory infection (SARI).
  • The data collection for the 2025-26 epidemiological year runs from 1 September 2025 to 31 August 2026.
  • By 11 of February 2026, 15 135 patients have been recruited in 33 hospitals across 15 Study Contributors in 5 European countries.

EMA Real-World Data Catalogue EUPAS1000000012

The latest protocol version can be found here.

  • Calculate the proportion of positive laboratory samples for viral respiratory pathogens
  • Characterise adult SARI patients
  • Prevalence of co-infection and impact on healthcare utilisation outcomes
  • Pathogen-specific SARI incidences
  • Feasibility assessments for future respiratory disease studies

COVID-19 Vaccine Effectiveness

  • The study was initiated at the request of AstraZeneca and Janssen in September 2021, and was joined later by Novavax, Valneva, and Pfizer to fulfil their regulatory commitments.
  • Multi-country hospital-based test-negative case-control design.
  • The data collection has been extended for the 2025-26 season.
  • By 11 of February 2026, 32 594 patients have been recruited across 39 hospitals in 7 European countries.

EMA Real-World Data Catalogue EUPAS42328.

The latest master protocol version can be found here.

  • Brand-specific COVID-19 vaccine effectiveness
Brand-specific COVID-19 vaccine effectiveness:
  • by SARS-CoV-2 genetic variants
  • within populations of special interest
  • by time since last dose
  • by time between doses
  • by number or type of doses given prior to last dose
  • Brand-specific COVID-19 vaccine effectiveness:
    • by severity level
    • by calendar time
    • by history and calendar time of prior infection
  • Effect of vaccination on length of hospital stay

RSV Vaccine Effectiveness

  • The study was initiated at the request of Pfizer in fall 2024.
  • Multi-country hospital-based test-negative case-control design.
  • The data collection has been extended for the 2025-26 season.
  • By 11 of February 2026, 1 134 patients have been recruited across 13 hospitals in 3 European countries.

EMA Real-World Data Catalogue EUPAS1000000035.

The latest protocol version can be found here.

  • Brand-specific RSV vaccine effectiveness
Brand-specific RSV vaccine effectiveness:
  • by RSV subtype A and B infection
  • by population of special interest
  • by time since vaccination
  • by calendar time
  • by modified SARI severity level

Multi-specimen pilot study

  • Pilot study to assess the detection of RSV, human metapneumovirus (hMPV), and parainfluenza virus (PIV) when using multi-specimen collection compared to a single nasopharyngeal swab.
  • Aim to gain insights into the possible underestimation of RSV, hMPV, and PIV detection rates in patients with an (severe) acute respiratory infection.
  • Prospective cohort pilot study conducted in a network of healthcare settings in Valencia (Spain).
  • This pilot study targets the enrolment of approximately 1000 (s)ARI patients.
  • As of 13 February 2026, 299 (s)ARI patients have been enrolled (of which 153 in the hospital setting).
  • Data collection running from 7 January 2026 until 31 July  2026.
  • Assess detection rates of RSV, hMPV and PIV in adult (s)ARI patients
  • Assess detection rates of RSV, hMPV and PIV:
    • by age categories, sex at birth, time since symptom onset categories, setting, diagnosis and common chronic conditions
  • Assess RSV detection rates by RSV vaccination status
  • Assess SARS-CoV-2 detection rates by SARS-CoV-2  vaccination status
  • Assess Influenza detection rates by Influenza vaccination status
  • Assess detection rates of co-infections
  • Assess detection rates of RSV, hMPV and PIV  by subtype or serotype
  • Assess detection rates of viral pathogens tested by multiplex panel RT-PCR